SPRED1 and neoplasm: Analogous to NF1, around 30% of MM cases with SPRED1 inactivation simultaneously exhibit KIT alterations, suggesting that SPRED1 inactivation may be in collaboration with other oncogenic events to stimulate tumor development (100).